...
首页> 外文期刊>Biological & pharmaceutical bulletin >Biodegradation and drug release of chitosan gel beads in subcutaneous air pouches of mice.
【24h】

Biodegradation and drug release of chitosan gel beads in subcutaneous air pouches of mice.

机译:小鼠皮下气囊中壳聚糖凝胶珠的生物降解和药物释放。

获取原文
获取原文并翻译 | 示例
           

摘要

Chitosan (CS) gel beads were prepared in 10% amino acid solution (pH 9) and implanted into air pouches (AP) prepared subcutaneously on the dorsal surface of mice. No inflammatory response was observed, and degradation of the beads in the AP increased as their degree of deacetylation decreased. Degradation could be altered by changing the nature of the CS or by increasing the CS concentration. The release of prednisolone (PS) in vivo from CS gel beads was similar to the release in vitro. When a suspension of PS was injected into the AP, the PS had almost completely disappeared 24 h after injection. Retention of PS in the AP was not increased by using a viscous CS solution. Alginate (Alg) gel beads, which were not degraded, released PS slowly into the AP over 3d. The in vitro release profile of PS using 1% CS (deacetylation: 70% (7B) and 80% (8B)) and 1.5% CS (deacetylation: 90% (9B)) gel beads was similar to that with Alg gel beads. However, the in vivo release of PS was affected by the degradability of the gel beads. CS7B and 8B (1%) gel beads had released PS into the AP earlier than 3 d according to their rate of degradation. CS9B (1.5%) gel beads were not degraded after 3 d and went on to release PS into the AP for 3 d similar to the release profile of Alg gel beads. CS9B (2%) gel beads were also not degraded after 3 d and the release of PS from these beads into the AP was sustained; 76% and 27% of administered PS remained in the gel beads after 1 and 3 d, respectively. Therefore, degradation and drug release of CS gel beads can be controlled by changing the structure of the gel matrix, which appears to make these beads a promising biodegradable vehicle for sustained drug delivery.
机译:在10%的氨基酸溶液(pH 9)中制备壳聚糖(CS)凝胶珠,并将其植入到在小鼠背侧皮下制备的气囊(AP)中。没有观察到炎性反应,并且AP中的珠的降解随着脱乙酰度的降低而增加。降解可以通过改变CS的性质或增加CS浓度来改变。泼尼松龙(PS)从CS凝胶珠体内的释放与体外释放相似。当将PS的悬浮液注射到AP中时,注射后24 h PS几乎完全消失了。通过使用粘性CS溶液,不会增加PS在AP中的保留率。未降解的藻酸盐(Alg)凝胶珠在3d内将PS缓慢释放到AP中。使用1%CS(脱乙酰基:70%(7B)和80%(8B))和1.5%CS(脱乙酰基:90%(9B))凝胶珠的PS的体外释放曲线与Alg凝胶珠相似。但是,PS的体内释放受到凝胶珠降解的影响。 CS7B和8B(1%)凝胶珠根据降解速率早于3 d将PS释放到AP中。 CS9B(1.5%)凝胶珠在3 d后未降解,并持续3 d将PS释放到AP中,类似于Alg凝胶珠的释放曲线。 CS9B(2%)凝胶珠在3 d后也未降解,并且PS从这些珠持续释放到AP中。 1天和3天后,分别有76%和27%的PS残留在凝胶珠中。因此,可以通过改变凝胶基质的结构来控制CS凝胶珠的降解和药物释放,这似乎使这些珠成为用于持续药物递送的有前途的生物可降解载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号